{"created":"2023-05-15T16:30:05.315845+00:00","id":1088,"links":{},"metadata":{"_buckets":{"deposit":"6629e0fb-2b6b-4c26-8695-7e1975732714"},"_deposit":{"created_by":2,"id":"1088","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"1088"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00001088","sets":["10:11"]},"author_link":["5220","5223","5222","5231","5234","5228","5225","5230","5232","5219","5226","5227","5229","5221","5224","5218","5233"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"E239","bibliographicPageStart":"E232","bibliographicVolumeNumber":"48","bibliographic_titles":[{"bibliographic_title":"Hepatology Research"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Aim: Direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection have a significantly high sustained virologic response rate after a short treatment course and do not have any severe adverse effects. Patient-reported outcomes (PROs) have become increasingly important to assess the total impact of a chronic disease. We aimed to evaluate the changes in symptoms of patients with HCV infection treated with DAAs by using PROs. Methods: A total of 107 patients with chronic HCV infection were treated with DAAs. Daclatasvir/asunaprevir or sofosbuvir/ledipasvir was used for HCV 1B infection, and sofosbuvir/ribavirin for HCV 2A/2B infection. The PROs measured at the start of treatment and 1 year after the start of treatment were cirrhosis-related symptom score (CSS), presence of restless legs syndrome (RLS), Epworth sleepiness scale (ESS), Pittsburg sleep quality index (PSQI), Kessler 6 score (K-6), and the SF-36 to measure quality of life (QOL). All patients had a sustained virologic response rate of 24. Results: The CSS, PSQI, K-6, and RLS scores were improved 1 year after beginning treatment. However, QOL had not recovered. Changes in total CSS were correlated with HCV genotype, sex, hypertensive drug use, serum low-density lipoprotein, and ESS at the start of treatment and RLS 1 year after the start of treatment. The factors that contributed to worsening of CSS were HCV genotype 2B and RLS 1 year after the start of treatment. Conclusion: Treatment with DAAs eliminated HCV-RNA and improved most symptoms, but QOL did not recover.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Hepatology Research, 48(3), pp.E232-E239; 2018","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本肝臓学会"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1111/hepr.12974","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2017 The Japan Society of Hepatology. This is the peer reviewed version of the following article: Hepatology Research, 48(3), pp.E232-E239; 2018, which has been published in final form at http://dx.doi.org/10.1111/hepr.12974. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"13866346","subitem_source_identifier_type":"ISSN"}]},"item_2_text_62":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"The Japan Society of Hepatology"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ichikawa, Tatsuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyaaki, Hisamitsu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miuma, Satoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Taura, Naota"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Motoyoshi, Yasuhide"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Akahoshi, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakamura, Satomi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakamura, Junpei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takahashi, Youichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Honda, Tetsurou"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yajima, Hiroyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Uehara, Ryouhei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hino, Naoyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Narita, Syouhei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tanaka, Hisaya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sasaki, Seina"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakao, Kazuhiko"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-18"}],"displaytype":"detail","filename":"HepRes48_E232.pdf","filesize":[{"value":"232.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"HepRes48_E232.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/1088/files/HepRes48_E232.pdf"},"version_id":"2f73da1e-bc17-4e8b-81dc-a526a65e4570"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"direct-acting antivirals","subitem_subject_scheme":"Other"},{"subitem_subject":"hepatitis C virus","subitem_subject_scheme":"Other"},{"subitem_subject":"patient-reported outcomes","subitem_subject_scheme":"Other"},{"subitem_subject":"quality of life, symptoms","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals"}]},"item_type_id":"2","owner":"2","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-03-01"},"publish_date":"2019-03-01","publish_status":"0","recid":"1088","relation_version_is_last":true,"title":["Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T04:07:49.420549+00:00"}